Latest news with #SYNT
Yahoo
08-08-2025
- Business
- Yahoo
Synthomer First Half 2025 Earnings: UK£0.22 loss per share (vs UK£0.18 loss in 1H 2024)
Explore Synthomer's Fair Values from the Community and select yours Synthomer (LON:SYNT) First Half 2025 Results Key Financial Results Revenue: UK£925.2m (down 9.8% from 1H 2024). Net loss: UK£35.9m (loss widened by 20% from 1H 2024). UK£0.22 loss per share (further deteriorated from UK£0.18 loss in 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Synthomer Earnings Insights Looking ahead, revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Performance of the British Chemicals industry. The company's shares are down 21% from a week ago. Risk Analysis You should learn about the 2 warning signs we've spotted with Synthomer (including 1 which shouldn't be ignored). Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBC
28-07-2025
- Entertainment
- CBC
Mac DeMarco's miraculous awakening, and 3 more songs you need to hear this week
Songs you need to hear is CBC Music's weekly list of hot new Canadian tracks. Scroll down to discover the songs our producers are loving right now. For even more new music, check out our SYNTH playlist on Youtube. Holy, Mac DeMarco Over an animated yet unadorned guitar riff, Mac DeMarco's voice quivers as he sings about a "miracle from above" on Holy: "Miracle/ Reveal yourself to me," he sings with his signature silvery twang. The indie singer-songwriter wrote and produced the lean track entirely on his own, and it serves as the second single from his forthcoming Aug. 22 album, Guitar. A simple bass line helps ground the melody, which is understated and gentle without feeling too sparse. In DeMarco's typical D.I.Y. fashion, he self-shot the track's accompanying music video, which transports listeners into the outdoors for a breezy walk: "I waded around in the ocean fully clothed for a couple hours and completely filled my boots with seawater," he shared. "There were some other shots on some rocks I kept trying too, but in the end, the clip of me falling in the garden and eating the apple was best." — Natalie Harmsen Good Buddy, Fontine Cover me up, spin me around, tell me you're not gonna leave. We're takin' it slow but I already know, you're a good buddy to me. With that joyful chorus Fontine is back, serving a grittier sound than the folk she introduced us to on her acclaimed 2023 debut EP, Yarrow Lover. Although Fontine is embracing a rock-star vibe this time around, ready to roll with a debut album set for Oct. 7, the centre of her songs are still heartfelt and vulnerable. Good Buddy, the forthcoming album's title track, is named after CB radio slang for "gay," and the queer artist from Winnipeg leans into the term, setting us up with a live-off-the-floor song filled with tiny, quiet moments of love. — Holly Gordon Annihilation, Tops There's always a sense of anxiety that floods in when thinking about the future, but that sentiment feels tenfold in this exact moment in time. Montreal indie-pop stalwart Tops has chosen to tackle this with "a mix of complacency and surrendering," as explained in a statement. That's not as dire as it sounds though; sometimes there's freedom in acknowledging "in the end, nothing is ever finished and you just gotta follow your heart." That is felt across their latest single, Annihilation, a slinky number that was built off the foundation of drummer Riley Fleck's fill-heavy rhythms. "Truth is I'm just barely getting by," sings Jane Penny, "When I lose control/ Will I surface and know/ That I've reached the end?" Complete with synths and a dramatic chorus breakdown, it's easy to get lost — and yes, surrender — to the song's undeniable grooves. — Melody Lau Rapture in Blue, Daniel Avery and Cécile Believe British producer and composer Daniel Avery announced his upcoming album Tremor last week, with the release of a new single featuring Cécile Believe. Rapture in Blue is buoyed by the Montreal (now L.A.-based) producer and singer's ethereal vocals that float over Avery's textural layers of slowed-down breakbeat and reverb. Clanging guitar comes in on the chorus as Cécile Believe reaches her upper register and glittering chords descend in the aftermath. It's a lush and effusive track that reveals more and more of its magic on repeat listens. This one's for the real yearners, as she sings in the second verse: "Every time you walk away/ A little piece of me goes/ A bittersweet, sticky feeling/ Only lovers can know." — Kelsey Adams
Business Wire
01-07-2025
- Business
- Business Wire
Syntis Bio Closes $38 Million Financing to Accelerate Oral Therapies for Obesity and Rare Diseases
BOSTON--(BUSINESS WIRE)-- Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, announced today the close of a $33 million oversubscribed Series A financing. Cerberus Ventures led the round, with participation from new investors Mansueto Investments, Woori Venture Partners and Apollo Labs. Founding investors BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures and Cerity Partners Ventures also participated. Syntis has also secured up to $5 million in non-dilutive funding from the National Institutes of Health (NIH) through two Fast-Track Small Business Innovation Research (SBIR) awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supporting the advancement of its SYNT™ (SYN thetic T issue-lining) platform. Capital from the Series A financing and grant funding will advance development of SYNT, an orally delivered, transient polymer coating for the small intestine that controls nutrient uptake, enhances gut-restricted enzyme efficacy and increases systemic drug absorption for up to 24 hours. The funding also enables the advancement of lead program SYNT-101 through Phase 1 studies as a once-daily treatment for obesity, as well as initiation of Phase 1 studies for SYNT-202, a first-in-class oral enzyme therapy for homocystinuria, a rare pediatric amino acid disorder. To date, SYNT-101 has demonstrated strong pre-clinical safety and weight loss data, as well as clinical advancements in safety, mechanism of action and pathways for controlling weight. 'We're grateful for the continued support and enthusiasm of our new and existing investors, who share our vision to revolutionize both chronic and rare disease treatment through safe, effective oral therapies,' said Rahul Dhanda, CEO and co-founder of Syntis Bio. "This oversubscribed Series A round coupled with these non-dilutive grants validates and accelerates the promise of SYNT-101 in obesity and, more broadly, our SYNT platform technology to unlock the small intestine's full therapeutic potential to meaningfully improve human health.' Syntis also announced the addition of two members to the company's Board of Directors, Chenny Zhang, director at Cerberus Ventures, and Michael Nannizzi, director of investments at W. R. Berkley. Mr. Dhanda added, 'I'm thrilled to welcome Chenny and Michael to our board. Michael has actively advised Syntis since our early days, reflecting W. R. Berkley's consistent strategic support, and adding Chenny augments the strong foundation we have built. Her extensive life sciences experience at Cerberus Ventures and previously at In-Q-Tel will be invaluable as Syntis Bio enters our next growth phase focused on strategic partnerships and platform innovation.' 'While high-cost, complex development processes continue to limit many Americans' access to essential medicines, Syntis' SYNT platform represents a fundamentally novel approach to the oral delivery of biologics. We believe SYNT, with its breakthrough technology and platform potential, is poised to significantly expand patient access and redefine what is possible in drug delivery,' said Ms. Zhang. 'I look forward to working closely with the team to realize the full potential of their disruptive platform and pipeline.' About SYNT-101 SYNT-101 is being developed as a once-daily pill for the treatment of obesity. SYNT-101 works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutrients to the distal small intestine to stimulate the natural secretion of satiety and metabolism-regulating hormones, including GLP-1. This mechanism, known as duodenal nutrient exclusion, is a key contributor to the efficacy of gastric bypass surgery, which remains the gold standard for weight loss and metabolic disease management. Recent preclinical data demonstrated 100% preservation of lean muscle mass with consistent 1% weekly weight loss in rodent models, while first-in-human data showed that SYNT-101 demonstrated strong evidence of nutrient redirection and satiety hormone modulation. Importantly, SYNT-101 displayed strong safety and tolerability across both studies, with no adverse events reported. About SYNT™ Technology SYNT-101 leverages the power of SYNT™ (SYN thetic T issue-lining) oral therapeutic technology that optimizes therapeutic effects in the small intestine, the body's nexus for metabolic control, digestion and drug absorption. SYNT uses mussel-inspired polymer chemistry to deliver a safe, transient polydopamine coating to catalase-rich tissues, like the duodenum. After successful deployment in the gastrointestinal tract, the polydopamine lining is sustained for up to 24 hours, after which it is naturally and safely cleared from the body. SYNT is highly versatile and can achieve a variety of therapeutic effects. In addition to nutrient exclusion, SYNT can be engineered to install and sustain gut-restricted enzymes in the small bowel, enhance the oral bioavailability of drugs, and target new tissues throughout the body. Data from more than 100 preclinical pig studies conducted by MIT and Syntis demonstrate that SYNT can achieve 70% glucose blocking, 20 times improved enzyme activity, and 4-10 times increased oral drug bioavailability. About Syntis Bio Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine's unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world's most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body's nexus for metabolic control, digestion and drug absorption. Alongside its lead obesity program, SYNT-101, the company is advancing a portfolio of therapies targeting orphan metabolic diseases and intestinal-related disorders. Syntis is headquartered in Boston, MA. For more information, please visit and follow us on LinkedIn. NIH Grant Acknowledgment Research reported in this press release was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Numbers R44DK138869 and R44DK141341. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
